{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-251014","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.624974+00:00","generated_at":"2026-05-30T05:26:11.415560+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcellx updates anito-cel data: Phase 1 median PFS 30.2 months; iMMagine-1 95% ORR","bullets":["Phase 1 study (38 patients): 100% ORR, 79% CR/sCR, median PFS 30.2 months at 38.1 months median follow-up; median OS not reached.","iMMagine-1 (58 patients): 95% ORR, 62% CR/sCR, median follow-up 10.3 months; 92% MRD negativity at 10^-5.","No delayed neurotoxicities (no parkinsonism, no cranial nerve palsies, no Guillain-Barré) observed across >140 patients dosed.","First patient dosed in iMMagine-3 study (earlier lines); manufactured by Kite with turnaround time in line with Kite's commercial products.","Data to be presented at ASH Annual Meeting Dec 7-10, 2024; company webcast Dec 9 at 8:30 p.m. PT."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-251014","json":"https://secwatch.observer/filing/0001193125-24-251014.json","markdown":"https://secwatch.observer/filing/0001193125-24-251014.md","text":"https://secwatch.observer/filing/0001193125-24-251014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000119312524251014/0001193125-24-251014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000119312524251014/d844485d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:26:11.415560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}